AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BIOPHARMA CREDIT PLC

Declaration of Voting Results & Voting Rights Announcements Nov 5, 2018

4973_rns_2018-11-05_2bd2c6d0-26c1-44e4-a05d-afc20b7f4143.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3485G

BioPharma Credit PLC

05 November 2018

BioPharma Credit PLC (the "Company")

Total Voting Rights

In conformity with the Disclosure Guidance and Transparency Rules, the Company notifies that the issued share capital and voting rights of the Company are as follows:

Class of share Total number of shares in circulation Number of voting rights attached to each share Total number of voting rights of shares in circulation Number of shares held in treasury (carrying no voting rights attached until issued) Total number of shares in issue
Ordinary $0.01 shares 1,373,932,067 1 1,373,932,067 0 1,373,932,067

The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in BioPharma Credit PLC under the FCA's Disclosure Guidance and Transparency Rules.

5 November 2018

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TVREAEFSELXPFFF

Talk to a Data Expert

Have a question? We'll get back to you promptly.